William Stilley, CEO of Adial Pharmaceuticals (NASDAQ: ADIL) sits down with BAF host Michelle Griego to discuss the company’s lead asset, AD04, as a potential genetically targeted treatment for alcohol and opioid use disorder.
William Stilley, CEO of Adial Pharmaceuticals (NASDAQ: ADIL) sits down with BAF host Michelle Griego to discuss the company’s lead asset, AD04, as a potential genetically targeted treatment for alcohol and opioid use disorder.
Sorry, the comment form is closed at this time.